PubRank

Daria J Hazuda

Author PubWeight™ 103.72‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008 7.33
2 Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe 2008 6.24
3 Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008 5.58
4 Host cell factors in HIV replication: meta-analysis of genome-wide studies. PLoS Pathog 2009 4.24
5 Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci U S A 2002 3.40
6 Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem 2008 3.09
7 Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem 2003 2.82
8 A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol 2009 2.30
9 Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS 2009 2.28
10 Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007 2.27
11 c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol 2007 2.24
12 HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med 2012 2.18
13 A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob Agents Chemother 2004 1.94
14 Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid. J Biol Chem 2002 1.80
15 PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination. J Immunol 2009 1.77
16 A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc Natl Acad Sci U S A 2005 1.74
17 Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells. J Med Chem 2003 1.55
18 MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 2012 1.48
19 Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J Virol 2010 1.46
20 Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob Agents Chemother 2005 1.38
21 Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV-infected macaques. J Clin Invest 2013 1.35
22 Structural basis for the inhibition of RNase H activity of HIV-1 reverse transcriptase by RNase H active site-directed inhibitors. J Virol 2010 1.32
23 Altering expression levels of human immunodeficiency virus type 1 gp120-gp41 affects efficiency but not kinetics of cell-cell fusion. J Virol 2002 1.29
24 Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities. Biochemistry 2005 1.25
25 Combined approaches for HIV cure. Curr Opin HIV AIDS 2013 1.23
26 Structure, stereochemistry, and biological activity of integramycin, a novel hexacyclic natural product produced by Actinoplanes sp. that inhibits HIV-1 integrase. Org Lett 2002 1.23
27 Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment. Antimicrob Agents Chemother 2010 1.16
28 Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother 2009 1.13
29 HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro. J Biol Chem 2006 1.10
30 A potent and orally active HIV-1 integrase inhibitor. Bioorg Med Chem Lett 2006 1.10
31 Potent and selective HIV-1 ribonuclease H inhibitors based on a 1-hydroxy-1,8-naphthyridin-2(1H)-one scaffold. Bioorg Med Chem Lett 2010 1.06
32 Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium. Ann N Y Acad Sci 2011 1.06
33 Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2010 1.04
34 Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology 2013 1.02
35 Monitoring the development of non-nucleoside reverse transcriptase inhibitor-associated resistant HIV-1 using an electrochemiluminescence-based reverse transcriptase polymerase assay. Anal Biochem 2007 0.95
36 Discovery of oxadiazoyl tertiary carbinamine inhibitors of beta-secretase (BACE-1). J Med Chem 2006 0.95
37 In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother 2013 0.93
38 Dihydroxypyridopyrazine-1,6-dione HIV-1 integrase inhibitors. Bioorg Med Chem Lett 2007 0.92
39 A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6]naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cells. Bioorg Med Chem Lett 2005 0.91
40 Isolation, structure, and HIV-1-integrase inhibitory activity of structurally diverse fungal metabolites. J Ind Microbiol Biotechnol 2004 0.90
41 Biochemical and cell-based assays for characterization of BACE-1 inhibitors. Anal Biochem 2005 0.90
42 Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial. Antivir Ther 2013 0.88
43 Potential new therapies for the treatment of HIV-1 infection. Annu Rev Med 2002 0.88
44 HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications. Drug Resist Updat 2004 0.88
45 Four novel bis-(naphtho-gamma-pyrones) isolated from Fusarium species as inhibitors of HIV-1 integrase. Bioorg Med Chem Lett 2003 0.87
46 Antiviral activity and in vitro mutation development pathways of MK-6186, a novel nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother 2012 0.86
47 Beta-secretase cleavage at amino acid residue 34 in the amyloid beta peptide is dependent upon gamma-secretase activity. J Biol Chem 2003 0.86
48 Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis. Virology 2013 0.85
49 Gene expression profiling of rat liver reveals a mechanistic basis for ritonavir-induced hyperlipidemia. Genomics 2007 0.85
50 Synthesis of 5-(1-H or 1-alkyl-5-oxopyrrolidin-3-yl)-8-hydroxy-[1,6]-naphthyridine-7-carboxamide inhibitors of HIV-1 integrase. Bioorg Med Chem Lett 2008 0.84
51 Assessment of the susceptibility of mutant HIV-1 to antiviral agents. J Virol Methods 2010 0.84
52 Novel mutations introduced at the beta-site of amyloid beta protein precursor enhance the production of amyloid beta peptide by BACE1 in vitro and in cells. J Alzheimers Dis 2005 0.84
53 Dissecting Tn5 transposition using HIV-1 integrase diketoacid inhibitors. Biochemistry 2007 0.83
54 A genotype 2b NS5B polymerase with novel substitutions supports replication of a chimeric HCV 1b:2b replicon containing a genotype 1b NS3-5A background. Antiviral Res 2005 0.82
55 Compounds that bind APP and inhibit Abeta processing in vitro suggest a novel approach to Alzheimer disease therapeutics. J Biol Chem 2005 0.81
56 8-Hydroxy-3,4-dihydropyrrolo[1,2-a]pyrazine-1(2H)-one HIV-1 integrase inhibitors. Bioorg Med Chem Lett 2007 0.81
57 Scintillation proximity assays for mechanistic and pharmacological analyses of HIV-1 integration. Methods 2009 0.80
58 Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors. Bioorg Med Chem Lett 2007 0.80
59 Isolation, structure, absolute stereochemistry, and HIV-1 integrase inhibitory activity of integrasone, a novel fungal polyketide. J Nat Prod 2004 0.80
60 Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors. J Med Chem 2015 0.79
61 Isolation, structure, and HIV-1 integrase inhibitory activity of Cytosporic acid, a fungal metabolite produced by a Cytospora sp. J Nat Prod 2003 0.79
62 A series of 5-aminosubstituted 4-fluorobenzyl-8-hydroxy-[1,6]naphthyridine-7-carboxamide HIV-1 integrase inhibitors. Bioorg Med Chem Lett 2006 0.78
63 Integramides A and B, two novel non-ribosomal linear peptides containing nine C(alpha)-methyl amino acids produced by fungal fermentations that are inhibitors of HIV-1 integrase. Org Lett 2002 0.78
64 Design and synthesis of substituted 4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxamides, novel HIV-1 integrase inhibitors. Bioorg Med Chem Lett 2007 0.77
65 10-Hydroxy-7,8-dihydropyrazino[1',2':1,5]pyrrolo[2,3-d]pyridazine-1,9(2H,6H)-diones: potent, orally bioavailable HIV-1 integrase strand-transfer inhibitors with activity against integrase mutants. Bioorg Med Chem Lett 2008 0.77
66 Purification of untagged HIV-1 reverse transcriptase by affinity chromatography. Protein Expr Purif 2010 0.77
67 Pharmacodynamic analysis of a serine protease inhibitor, MK-4519, against hepatitis C virus using a novel in vitro pharmacodynamic system. Antimicrob Agents Chemother 2011 0.76
68 Rapid P1 SAR of brain penetrant tertiary carbinamine derived BACE inhibitors. Bioorg Med Chem Lett 2010 0.76
69 Total synthesis, characterization, and conformational analysis of the naturally occurring hexadecapeptide integramide A and a diastereomer. Chemistry 2010 0.76
70 Isolation, structure and HIV-1 integrase inhibitory activity of exophillic acid, a novel fungal metabolite from Exophiala pisciphila. J Antibiot (Tokyo) 2003 0.76
71 Complete absolute configuration of integramide A, a natural, 16-mer peptide inhibitor of HIV-1 integrase, elucidated by total synthesis. Chembiochem 2009 0.76
72 Triple Hyp→Pro replacement in integramide A, a peptaib inhibitor of HIV-1 integrase: Effect on conformation and bioactivity. Biopolymers 2011 0.75
73 Integracides: tetracyclic triterpenoid inhibitors of HIV-1 integrase produced by Fusarium sp. Bioorg Med Chem 2003 0.75
74 Chemistry and structure-activity relationship of HIV-1 integrase inhibitor integracide B and related natural products. J Nat Prod 2003 0.75
75 Correction to Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors. J Med Chem 2015 0.75
76 SAR of tertiary carbinamine derived BACE1 inhibitors: role of aspartate ligand amine pKa in enzyme inhibition. Bioorg Med Chem Lett 2010 0.75